Pfizer Inc. (PFE)

PFE Income Statement

Revenue, expenses, and profitability analysis

PFE Quarterly Income Statement (USD)

Quarterly Report	TTM	03/29/2026	12/31/2025	09/28/2025	06/29/2025	03/30/2025	03/29/2025	12/31/2024	09/29/2024
Gross Profit	43.907B	9.720B	12.285B	12.482B	9.420B	9.827B	—	12.968B	10.771B
Revenue	63.315B	14.451B	17.557B	16.654B	14.653B	13.715B	—	17.763B	17.702B
Cost of Goods Sold	19.408B	4.731B	5.272B	4.172B	5.233B	3.888B	—	4.795B	6.931B
Gross Profit Margin	67.3%	67.3%	70.0%	74.9%	64.3%	71.7%	—	73.0%	60.8%
Total Operating Expenses	29.062B	5.688B	8.597B	8.932B	5.845B	5.203B	—	7.243B	5.803B
Research & Development	12.424B	2.627B	3.418B	3.936B	2.443B	2.179B	—	3.017B	2.565B
Selling, General & Administrative	13.283B	2.961B	3.734B	3.186B	3.402B	3.024B	—	4.226B	3.238B
Operating Income (EBIT)	14.845B	4.032B	3.688B	3.550B	3.575B	4.624B	—	5.725B	4.968B
Operating Margin	27.9%	27.9%	21.0%	21.3%	24.4%	33.7%	—	32.2%	28.1%
Income Before Tax (EBT)	7.906B	3.170B	-1.642B	3.334B	3.044B	2.784B	—	-10.000M	4.715B
Interest Income	575.000M	115.000M	166.000M	138.000M	156.000M	143.000M	—	170.000M	116.000M
Interest Expense	2.685B	668.000M	711.000M	652.000M	654.000M	654.000M	—	739.000M	783.000M
Other Income/Expense	-6.939B	-862.000M	-5.330B	-216.000M	-531.000M	-1.840B	—	-5.735B	-253.000M
Net Income	7.491B	2.688B	-1.648B	3.541B	2.910B	2.967B	—	403.000M	4.473B
Income Tax Expense	384.000M	461.000M	-2.000M	-216.000M	141.000M	-189.000M	—	-421.000M	234.000M
Net Profit Margin	18.6%	18.6%	-9.4%	21.3%	19.9%	21.6%	—	2.3%	25.3%
EBITDA	16.942B	5.215B	756.000M	5.648B	5.323B	5.056B	—	5.143B	7.253B
EBITDA Margin	36.1%	36.1%	4.3%	33.9%	36.3%	36.9%	—	29.0%	41.0%
Depreciation & Amortization	6.157B	1.183B	1.687B	1.662B	1.625B	1.618B	—	1.791B	1.755B
EPS Basic	1.31	0.47	-0.29	0.62	0.51	0.52	—	0.07	0.79
EPS Diluted	1.31	0.47	-0.29	0.62	0.51	0.52	—	0.07	0.78
Shares Outstanding	5.691B	5.691B	5.683B	5.685B	5.685B	5.675B	—	5.667B	5.667B
Diluted Shares Outstanding	5.731B	5.731B	5.686B	5.714B	5.706B	5.710B	—	5.703B	5.705B

PFE Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Gross Profit	44.014B	41.846B	30.340B	62.090B	46.875B	29.880B	28.549B	37.639B
Revenue	62.579B	63.627B	59.553B	100.330B	81.288B	41.651B	41.172B	53.647B
Cost of Goods Sold	18.565B	21.781B	29.213B	38.240B	34.413B	11.771B	12.623B	16.008B
Gross Profit Margin	70.3%	65.8%	50.9%	61.9%	57.7%	71.7%	69.3%	70.2%
Total Operating Expenses	28.577B	25.363B	25.048B	24.541B	26.082B	20.795B	21.038B	22.350B
Research & Development	11.976B	10.738B	10.578B	11.426B	13.828B	9.395B	8.364B	7.967B
Selling, General & Administrative	13.346B	14.730B	14.470B	13.115B	12.254B	11.400B	12.674B	14.383B
Operating Income (EBIT)	15.437B	16.483B	5.292B	37.549B	20.793B	9.085B	7.511B	15.289B
Operating Margin	24.7%	25.9%	8.9%	37.4%	25.6%	21.8%	18.2%	28.5%
Income Before Tax (EBT)	7.520B	8.023B	1.058B	34.729B	24.311B	7.036B	11.485B	11.885B
Interest Income	603.000M	545.000M	1.624B	251.000M	36.000M	73.000M	225.000M	333.000M
Interest Expense	2.671B	3.091B	2.209B	1.238B	1.291B	1.449B	1.573B	1.316B
Other Income/Expense	-7.917B	-8.460B	-4.234B	-2.820B	3.518B	-2.049B	3.974B	-3.404B
Net Income	7.770B	8.020B	2.133B	31.365B	22.147B	9.159B	16.273B	11.153B
Income Tax Expense	-266.000M	-28.000M	-1.114B	3.328B	1.852B	370.000M	618.000M	706.000M
Net Profit Margin	12.4%	12.6%	3.6%	31.3%	27.2%	22.0%	39.5%	20.8%
EBITDA	15.096B	18.127B	9.557B	41.031B	30.793B	13.168B	18.853B	19.585B
EBITDA Margin	24.1%	28.5%	16.0%	40.9%	37.9%	31.6%	45.8%	36.5%
Depreciation & Amortization	4.905B	7.013B	6.290B	5.064B	5.191B	4.681B	5.795B	6.384B
EPS Basic	1.36	1.42	0.38	5.59	3.95	1.65	2.92	1.90
EPS Diluted	1.36	1.41	0.37	5.47	3.88	1.63	2.87	1.87
Shares Outstanding	5.683B	5.664B	5.643B	5.608B	5.601B	5.555B	5.569B	5.872B
Diluted Shares Outstanding	5.686B	5.700B	5.709B	5.733B	5.708B	5.632B	5.675B	5.977B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY

81,000 employees

www.pfizer.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Albert Bourla

View full financials